Please use this identifier to cite or link to this item:
doi:10.22028/D291-35478
Title: | COVID-19 and Intracranial Hemorrhage: A Multicenter Case Series, Systematic Review and Pooled Analysis |
Author(s): | Schmidbauer, Moritz L. Ferse, Caroline Salih, Farid Klingner, Carsten Musleh, Rita Kunst, Stefan Wittstock, Matthias Neumann, Bernhard Schebesch, Karl-Michael Bösel, Julian Godau, Jana Lochner, Piergiorgio Adam, Elisabeth H. Jahnke, Kolja Knier, Benjamin Schirotzek, Ingo Müllges, Wolfgang Notz, Quirin Dengl, Markus Güldner, Andreas Onur, Oezguer A. Garcia Borrega, Jorge Dimitriadis, Konstantinos Günther, Albrecht on behalf of the IGNITE Study Group |
Language: | English |
Title: | Journal of Clinical Medicine |
Volume: | 11 |
Issue: | 3 |
Publisher/Platform: | MDPI |
Year of Publication: | 2022 |
Free key words: | COVID-19 intracranial hemorrhage prognosis anticoagulation |
DDC notations: | 610 Medicine and health |
Publikation type: | Journal Article |
Abstract: | Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3% of patients experienced the critical stage of COVID-19, 62.7% of patients were on anticoagulation and 27.5% of the patients received ECMO. The prevalence of ICH was at 0.85% and the mortality at 52.18%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future. |
DOI of the first publication: | 10.3390/jcm11030605 |
Link to this record: | urn:nbn:de:bsz:291--ds-354786 hdl:20.500.11880/32413 http://dx.doi.org/10.22028/D291-35478 |
ISSN: | 2077-0383 |
Advisor: | Attribution 4.0 International (CC BY 4.0) |
Date of registration: | 18-Feb-2022 |
Description of the related object: | Supplementary Materials |
Related object: | https://www.mdpi.com/article/10.3390/jcm11030605/s1 |
Faculty: | M - Medizinische Fakultät |
Department: | M - Neurologie und Psychiatrie |
Professorship: | M - Keiner Professur zugeordnet |
Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-11-00605.pdf | 3,01 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License